Interv Akut Kardiol. 2002;1(1):21-27

Influence of infarct related artery reperfusion before primary coronary angioplasty

Stanislav Šimek1, Michael Aschermann1, František Holm2, Jiří Humhal1, Aleš Linhart1, Miroslav Pšenička1, Libor Hemžský1, Jan Vojáček3,4
1 II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha
2 Kardiologické oddělení, Krajská nemocnice Liberec
3 I. interní klinika Fakultní nemocnice v Hradci Králové
4 Kardiocentrum dospělých, oddělení invazivní kardiologie interní kliniky 2. LF UK a FN Motol, Praha

Objectives: To investigate the prevalence of total coronary occlusion during the early hours of acute myocardial infarction (AMI). To evaluate the effect of infarct artery reperfusion before primary coronary angioplasty on short-term and long-term prognosis of patients with AMI.

Methods: 278 consecutive patients with AMI treated with primary coronary angioplasty were followed for 38 ± 12 months. The study population was divided into 2 groups according to the presence (group A, n = 33) or absence (group B, n = 245) of infarct related artery TIMI (Thrombolysis In Myocardial Infarction) flow ≥ 2 on the preintervention angiogram. The occurrence of reinfarction, congestive heart failure, coronary arteries reintervention and death during follow-up were investigated.

Results: Baseline characteristics were similar between the 2 groups. More patient in group B had cardiogenic shock (11 % vs. 0 %, p = 0,045). Success rate of primary PTCA (ability to achieve TIMI ≥ 2 ) was higher in group A (100 % vs. 89,4 %, p = 0,046). Ejection fraction of left ventricle was insignificantly higher in group A (52 % vs. 47 %, ns), peak levels of creatine kinase were lower in group A (20 ± 21 vs. 38 ± 29 µkat/l, ns). In group A there was a trend to lower 30 day mortality (0 % vs. 7,8 %, p = 0,09), lower need to urgent repeated coronary angioplasty (0 % vs.8,6 %, p = 0,08) within 30 days. Congestive heart failure within 30 days was more frequent ( 22,9 % vs. 6,1 %, p = 0,026) and long-term mortality was higher (17,1 % vs. 3 %, p = 0,037) in group B.

Conclusions: Prevalence of infarct related artery reperfusion before primary angioplasty in our population was lower compared to previous studies. Reperfusion of infarct related artery before primary coronary angioplasty is associated with higher procedure success rate, smaller infarct size, lower incidence of congestive heart failure, lower need of urgent revascularization and lower long term mortality.

Keywords: primary angioplasty, reperfusion before intervention.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šimek S, Aschermann M, Holm F, Humhal J, Linhart A, Pšenička M, et al.. Influence of infarct related artery reperfusion before primary coronary angioplasty. Interv Akut Kardiol. 2002;1(1):21-27.
Download citation

References

  1. Brown KWG, Mac Millan RL, Forbath N, et al. Coronary unit:an intensive care centre for acute myocardial infarction. Lancet 1963;2:349-352. Go to original source... Go to PubMed...
  2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
  3. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682. Go to original source... Go to PubMed...
  4. The Beta Blocker Pooling Project Research Group. The Beta Blocker Pooling Project (BBPP):subgroup findings from randomized trials in postinfarction patients. Eur Heart J 1988;9:8-16. Go to original source...
  5. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from a myocardial infarction. JAMA 1980;243: 661-669. Go to original source...
  6. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303: 897-902. Go to original source... Go to PubMed...
  7. Reimer KA, Jennings RB. The wavefront phenomenon of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633-644.
  8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction:ISIS-2. Lancet 1988;2:349-360.
  9. French JK, Hyde TA, White HD. Left ventricular function following thrombolytic therapy for myocardial infarction. J Interven Cardiol 1998;11:9-18. Go to original source...
  10. Gregor P, Widimský P, et al. Kardiologie, 2. vydání, Galén Praha:1999: 190.
  11. Simes RJ, Topol EJ, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995;91:1923-1928. Go to original source... Go to PubMed...
  12. White HD, Van de Werf FJJ. Clinical cardiology:new frontiers:thrombolysis for acute myocardial infarction. Circulation 1998;97:1632-1646. Go to original source... Go to PubMed...
  13. Nijland F, Kamp O, Verheugt FW, Veen G, Visser CA. Long-term implications of reocclusion on left ventricular size and function after successful thrombolysis for first anterior myocardial infarction. Circulation 1997;95:111-117. Go to original source... Go to PubMed...
  14. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty infarction:a quantitative review. JAMA 1997;278:2093-2098. Go to original source... Go to PubMed...
  15. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-588. Go to original source... Go to PubMed...
  16. Simoons ML, Arnold AER, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction:no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-203. Go to original source... Go to PubMed...
  17. Brodie B, Thomas D. Stuckey, MD, Charles Hansen, MA, and Denise Muncy, RN, Benefit of Coronary Reperfusion Before Intervention on Outcomes After Primary Angioplasty for Acute Myocardial Infarction. Am J Cardiol 2000;85:13-18. Go to original source... Go to PubMed...
  18. Gustafson JG, Cox D, Garcia E, et al. Spontaneous patency in the early hours of AMI:incidence, predictors and prognostic implications (abstr). Circulation 1998;98(suppl I):1-22.
  19. Ross AM, Coyne KS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction:the PACT trial. J Am Coll Cardiol 1999;34: 1954-1962. Go to original source... Go to PubMed...
  20. Hatada K, Sugiura T, Kanihata H, et al. Clinical significance of coronary flow to the infarct zone before succesful primary PTCA in acute myocardial infarction. Chest 2001;120:1959-1963. Go to original source... Go to PubMed...
  21. Leiboff RH, Katz RJ, Wasserman AD, et al. A randomized, angiographically controlled trial of intracoronary streptokinase in acute myocardial infarction. Am J Cardiol 1984;53:404-407. Go to original source... Go to PubMed...
  22. Rogers WJ, Hood WP, Mantle JA, et al. Return of left ventricular function after reperfusion in patients with myocardial infarction:importance of subtotal stenoses or intact collaterals. Circulation 1984;69:338-349. Go to original source... Go to PubMed...
  23. Brodie BR, Weintraub RA, Hansen CJ, et al. Factors that predict improvement in left ventricular ejection fraction after coronary angioplasty for acute myocardial infarction. Cathet Cardiovasc Diagn 1987;13:372-380. Go to original source... Go to PubMed...
  24. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902. Go to original source... Go to PubMed...
  25. Widimský P, Groch L, Želízko M, Aschermann M, Bednář F. Multicentre randomized trial comparing transport to primary angioplasty vs immediate trombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a cathetrisation laboratory. The PRAGUE study. Eur Heart J 2000;21(10):823-831. Go to original source... Go to PubMed...
  26. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-1437. Go to original source... Go to PubMed...
  27. Bleich SD, Nichols T, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-1417. Go to original source... Go to PubMed...
  28. Bono D de, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis:results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-128. Go to original source... Go to PubMed...
  29. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342: 759-766. Go to original source...
  30. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I:a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:142-154. Go to original source... Go to PubMed...
  31. Verheugt FWA, Marsh RC, Veen G, Liem A, Zijlstra F. High-dose bolus heparin as initial therapy prior to primary angioplasty for acute myocardial infarction:results of the HEAP pilot study. J Am Coll Cardiol 1998;31:289-293. Go to original source... Go to PubMed...
  32. Braga JC, Esteves FP, Esteves JP, et al. Confirmation that heparin is an alternative means of promoting early reperfusion. Coron Artery Dis 1998;9:335-338. Go to original source... Go to PubMed...
  33. Simoons ML, Van den Brand M, De Zwaan C, et al. Improved survival after early thrombolysis in acute myocardial infarction:a randomized trial by the Interuniversity Cardiology Institute in The Netherlands. Lancet 1985;2:578-581. Go to original source... Go to PubMed...
  34. Liem A, Zijlstra F, Ottervanger JP, Hoorntje JC, Suryapranata H. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction:the Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol 2000 Mar 1;35(3):600-604. Go to original source... Go to PubMed...
  35. Ross AM, Molhoek P, Lundergan C, et al. A randomized comparison of low-molecular-weight-heparin enoxaparin and unfractiobnated heparin adjunctive to t-PA thrombolysis ans aspirin (HEART II). Circulation 2001;104:648-652. Go to original source... Go to PubMed...
  36. Van de Werf F, Armstrong PW, Granger C, et al. Efficacy and safety of tecteplase in combination with enoxaparin, abciximab or unfractionated heparin:the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 200;358:605-613.
  37. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators:observations in animals and humans. Circulation 1997;95: 1755-1759. Go to original source... Go to PubMed...
  38. Merkhof L, Zijlstra F, Olsson H, et al. Abciximab in the Treatment of Acute Myocardial Infarction Eligible for Primary Percutaneous Transluminal Coronary Angioplasty Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study. J Am Coll Cardiol 1999;33:1528-1532. Go to original source... Go to PubMed...
  39. Montalescot G, Barragan P, Wittenberg O, et al. for the ADMIRAL investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903. Go to original source... Go to PubMed...
  40. Antman EM, Giugliano RP, Gibson CM, et al. For the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Abciximab facilitates the rate and the extent of thrombolysis:results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999;99:2720-2732. Go to original source... Go to PubMed...
  41. Ohman EM. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for patency enhancement in the emergency department (SPEED) group. Circulation 2000;101(24):2788-2794. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.